SCT A01 for high-risk outpatients with early COVID-19
Part of Infections, Lungs & breathing clinical trials.
This trial tests SCTA01 (or a placebo) in people who are not hospitalized but have early COVID-19 symptoms and higher risk of getting very sick. It may help prevent worsening illness by acting soon after infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18+). If you can get pregnant, you’re not pregnant and agree to effective birth control during the study.
- You have COVID-19 symptoms and they started within the last 7 days.
- You have at least 2 COVID-19 symptoms and at least one COVID-19 risk factor.
- Your first positive COVID-19 test (PCR or antigen) was done within 3 days before treatment starts.
- You are currently not in the hospital and don’t expect to need hospitalization within 72 hours.
- You have not had a prior COVID-19 infection, and you have not recently received certain COVID-19 treatments or shots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antiviral pill, secutrelvir, for people with mild to moderate covid-19 who are at higher risk of getting seriously ill. It aims to see if the drug can prevent hospitalization or severe disease.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests a new drug called B10-FC in two groups: healthy volunteers and people recently diagnosed with mild-to-moderate COVID-19. It aims to check the drug's safety, how the body processes it, and how the immune system responds. The results will help decide if the drug should be studied further.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This Phase 1 trial tests a donated immune-cell treatment (T cells) to help immunocompromised people fight or resist COVID-19 after they recently received a bone marrow or stem cell transplant. It aims to see if the treatment is safe and if it helps the body respond better to the virus.
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.